Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J
Frontiers in Public Health
In 2024, the top-selling prescription drugs in the US reflect the diverse health challenges we face, from cancer and diabetes to autoimmune diseases and HIV
However, one impetus for the study was clinical encounters in which patients express concerns over drug safety
US$ 26.76
US$ 24.61
US$ 25.67
US$ 21.39
US$ 27.58
US$ 25.16
US$ 24.32
US$ 25.44
